RN
Cartesian Therapeutics, Inc.
RNAC · NASDAQ
$8.08 +0.25% (+$0.02)
1M -19.68%
Market Cap $237.4M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 160.73x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining Rev. growth 70.66%
EPS growth N/A
Book val. growth N/A
Profitability
0 /100
Weak Gross margin 766.42%
FCF margin 5,291.54%
Net margin 10,422.50%
Quality
0 /100
Poor ROIC 30.78%
Asset turnover 0.00x
ROA 48.31%
Debt
43 /100
Moderate Current ratio 7.48x
Int. coverage -188.07x
Debt/Equity N/A
Stability
26 /100
Unstable Beta 0.62x
Profitable years 0
Rev. volatility 77.97%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na RNAC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Carsten Brunn
Employees
75
Headquarters
Frederick
Nadcházející události
05 LIS
Earnings
Upcoming earnings report